Text and Data Mining valid from 2019-09-02
Received: 17 April 2019
Accepted: 6 June 2019
First Online: 2 September 2019
Ethics approval and consent to participate
: The study was approved by the Ethics committee of Section Center Area of Calabria Region based at the A.O.U. Mater Domini in Via Tommaso Campanella, 115, Catanzaro (approval with protocol number n. 259), and informed written consent was obtained from RSs.
: Not applicable.
: Menzella, Pellegrini, Cappuccio, Napolitano and Marini have no conflicts of interest to disclose. Pelaia hereby states to have received lecture fees and advisory board fees from: AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi, Dompè, GSK, Guidotti/Malesci, Menarini, Mundipharma, Novartis, TEVA, Zambon. Policreti and Porpiglia are employees of Novartis Italia.